Favipiravir is an inhibitor of Influenza viruses A, B, and C (IC50s: A = 0.03-0.20 µg/mL H1N1, 0.01-0.30 H2N2, 0.08-0.48 H3N2, 0.14-0.15 H4N2, 0.24-1.60 H7N2, 0.20-0.82 H5N1, 0.35 H1N2; B = 0.04-0.09 µg/mL; C = 0.03-0.06 µg/mL) as well as strains resistant to adamantane-type antivirals,...
Know who made it. See the evidence. Buy through one marketplace.
Favipiravir is an inhibitor of Influenza viruses A, B, and C (IC50s: A = 0.03-0.20 µg/mL H1N1, 0.01-0.30 H2N2, 0.08-0.48 H3N2, 0.14-0.15 H4N2, 0.24-1.60 H7N2, 0.20-0.82 H5N1, 0.35 H1N2; B = 0.04-0.09 µg/mL; C = 0.03-0.06 µg/mL) as well as strains resistant to adamantane-type antivirals, oseltamivir, and zanamivir. It displayed no cytotoxicity in a variety of cells. Favipiravir selectively inhibits viral RNA-dependent RNA polymerase. Favipiravir has also shown activity against other viruses including arena, phlebo, hanta, flavi, entero, alpha, respiratory syncytial, and noroviruses. In clinical trials for treatment of SARS-CoV-2
This product is manufactured by TriBio Science and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
